This week's top stories include breaking FDA approvals, insights on AI-assisted front desk management, and more.
|Articles|September 10, 2020
OD test drives meibographer, shares pros and cons
Advertisement
Melanie Denton Dombrowski, OD, FAAO, MBA, is launching a dry eye clinic and shopping for new equipment. In her research, she test drove Meibox Meibographer (Box Medical Solutions) for a few weeks. Dr. Denton weighs in on her take after a few days. She discusses pros and cons and shares several images she captured with the device.
Disclosure: Dr. Denton sits on the Bausch + Lomb speakers bureau; consults with Alcon, Optase, and Visus; and earns affiliate income from Èyes Are The Story
Advertisement
Related to this article
Open-access OCTA tools showed similar reliability, but different vessel density values in glaucoma; researchers advise using one tool consistently.
Diana Canto-Sims, OD, introduces the second guest of Season 2, Raphael Rostenne, who will be discussing AI-assisted front desk management.
For Maria Sampalis, OD, implementing AI isn't an excuse for practice owners to replace their staff with new technology; it should instead lift the burden of certain tasks to make for more patient visits.
IDOC's 2025 benchmarks from 175-plus independent OD practices put median practice net at 31% of revenue as variable costs fell for the first time since tracking began.
Maria Sampalis, OD, discusses her implementation of the EHR software Barti in her practice.
Host Hamza Shah, OD, MS, FAAO, is joined by Cory Lappin, OD, MS, FAAO, to discuss dynamic muscle stimulation for dry eye, spurred by a paper on improving blinking in dry eye patients.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
More than monitoring: Using AMD visits to promote healthy vision aging
2
FDA approves Brytly eye drops for ocular redness relief lasting up to 12 hours
3
Study: OCTA analysis tools report different macular vessel density values for glaucoma
4
Brepocitinib for noninfectious uveitis meets all phase 3 trial end points
5